# BPC-157 dosage & reconstitution (5 mg vial)

BPC-157 dosage: calculations for a 5 mg vial use the same amounts described in the literature. Adding 1 mL of bacteriostatic water produces 5 mg/mL, so each U-100 unit contains 50 mcg.

- **Vial contents:** 5 mg BPC-157
- **Final volume:** 1 mL
- **Concentration:** 5 mg/mL
- **One U-100 unit:** 50 mcg in 0.01 mL

## Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing

### Standard / Gradual Approach (1 mL = ~5 mg/mL)

| Week / phase | Daily dose | Units per injection (mL) |
|---|---|---|
| Weeks 1–2 | 200 mcg | 4 units (0.04 mL) |
| Weeks 3–4 | 400 mcg | 8 units (0.08 mL) |
| Weeks 5–8+ | 600 mcg | 12 units (0.12 mL) |

Frequency: Once daily, subcutaneously, at a consistent time.

### Reconstitution Steps

1. Draw 1 mL of bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid shaking to prevent foaming.
3. Gently swirl or roll until fully dissolved (clear solution).
4. Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.

Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

## U-100 Conversion Table

| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 50 injections |
| 5 | 0.05 mL | 250 mcg | 20 injections |
| 10 | 0.10 mL | 500 mcg | 10 injections |
| 20 | 0.20 mL | 1 mg (1000 mcg) | 5 injections |
| 30 | 0.30 mL | 1.5 mg (1500 mcg) | 3 injections |
| 50 | 0.50 mL | 2.5 mg (2500 mcg) | 2 injections |
| 100 | 1.00 mL | 5 mg (5000 mcg) | 1 injection |

## Supplies Needed

**BPC-157 vials (5 mg each)**
- Standard / Gradual Approach, 12 weeks: Minimum 9 vials (42 mg required).
- Standard / Gradual Approach, 24 weeks: Minimum 19 vials (92.4 mg required).

**U-100 syringes (1 mL)**
- Standard / Gradual Approach, 12 weeks: 84 new syringes for 84 injections.
- Standard / Gradual Approach, 24 weeks: 168 new syringes for 168 injections.

**Bacteriostatic water**
- Standard / Gradual Approach, 12 weeks: 9 mL total (1 mL per vial) → 3 × 3 mL vials.
- Standard / Gradual Approach, 24 weeks: 19 mL total (1 mL per vial) → 7 × 3 mL vials.

**Alcohol swabs**
- Standard / Gradual Approach, 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Standard / Gradual Approach, 24 weeks: 336 minimum; one box of 100 does not cover the calculation.

## Storage Instructions

- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.

## How This Works

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide with sequence GEPPPGKPADDAGLV (MW: 1419.55 Da), originally derived from the human gastric protective fraction. This partial gastro-protective peptide exhibits extraordinary regenerative properties across multiple organ systems. Molecular characteristics: Structure: 15 amino acids in specific configuration Stability: high resistance to acidic pH (1.5-7.4) and digestive enzymes No direct homology to known endogenous proteins Moderate lipophilicity: allows oral absorption and tissue penetration Does not require specific transporters Multisystem Pleiotropic Mechanisms: Angiogenic System (VEGF): VEGF-A upregulation: 200-400% increase in injured tissues (Seiwerth et al., 2018) VEGFR-2 stimulation: activation of ERK1/2 and Akt cascades Endothelial tubular formation: 300% improvement in Matrigel assays Capillary stabilization: increased pericytes/vascular coverage Growth Factor Modulation: EGF (Epidermal Growth Factor): +150% expression FGF-2 (Fibroblast Growth Factor): +180% in tendons (Chang et al., 2014) TGF-β (Factor Transformante): balance Smad2/3 vs Smad7 IGF-1: local increase in musculoskeletal tissue Nitric…

## Research FAQ

**Q: Is BPC-157 superior to TB-500 for tendon studies?** R: Ambos efectivos pero mecanismos complementarios. BPC-157 excele en:
**Q: Optimal protocol for intestinal barrier research?** R: Modelo colitis DSS en ratones:
**P: ¿BPC-157 cruza barrera hematoencefálica efectivamente?** A: Yes, studies confirm CNS penetration:
**Q: Is BPC-157 stable in gastric acid?** R: Extraordinariamente estable:
**Q: Interactions with NSAIDs or corticosteroids?** R: BPC-157 demuestra efectos sinérgicos protectores:

## References

1. Modelo preclínico murino
2. Park JM, et al. (2020) “Stable gastric pentadecapeptide BPC-157 heals cysteamine-colitis through rescue of intestinal stem cells” – Inflammation 43(4):1363-1376. [PubMed: 32075892]
3. Kang EA, et al. (2023) “BPC-157 as potential therapeutic agent in tendon injury” – Molecules 28(3):1305. [PubMed: 36722448]
4. Sikiric P, et al. (2016) “Focus on ulcerative colitis: stable gastric pentadecapeptide BPC-157” – Curr Pharm Des 22(30):4643-4651. [PubMed: 27444293]
5. Lee E, et al. (2021) “BPC-157 recovers testicular spermatogenesis in rats” – Acta Histochem 123(1):151653. [PubMed: 33632567]
6. Seiwerth S, et al. (2018) “BPC-157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons learned and novel therapeutic implications” – Curr Pharm Des 24(18):1995-2011. [PubMed: 29879887]
7. Tohyama S, et al. (2020) “BPC-157 accelerates healing of experimental colitis” – J Physiol Pharmacol 71(3):147-160. [PubMed: 32443215]
8. Park JM, et al. (2022) “Gastroprotection by BPC-157 and L-arginine on MPTP-induced gastric lesion” – World J Gastroenterol 28(5):535-548. [PubMed: 35166134]
9. Amic F, et al. (2018) “Bypassing major venous occlusion and duodenal lesions in rats: stable gastric pentadecapeptide BPC-157” – World J Gastroenterol 24(47):5366-5378. [PubMed: 30235425]

---
Source: https://protocolopeptidos.com/en/compuestos/bpc-157-5mg · Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.